Pharm: All Cardio Drugs Combined Flashcards Preview

MHD/Pharm Block 4 > Pharm: All Cardio Drugs Combined > Flashcards

Flashcards in Pharm: All Cardio Drugs Combined Deck (30):
1

Heparin

MOA: Complex w/ ATIII to inactivate IIa and Xa, inhibit XI and XII, Releases TFPI; Indication: DVT, PE, Anticoagulation

2

LMW Heparin (Enoxaparin)

MOA: Complex w/ ATIII to inactivate IIa and Xa, inhibit XI and XII, Releases TFPI; Indication: DVT, PE, Anticoagulation

3

Fondaparinux

MOA: Complex w/ ATIII to inactivate IIa and Xa; Indication: DVT, PE

4

Argatroban

MOA: Directly inhibits IIa; Indication: Anticoagulation in HIT patients

5

Bivalirudin/Hirudin

MOA: Directly inhibits IIa; Indication: Anticoagulation in HIT patients

6

AT Concentrate

MOA: Directly inhibits IIa; Indication: DIC, sepsis, thrombophilia

7

Protamine Sulfate

MOA: Antagonizes Heparin; Indication: Heparin overdose

8

Warfarin

MOA: Antagonizes Vitamin K epoxide reductase, preventing activation of II, VII, IX, X.; Indication: DVT, Afib, Hypercoaguable state

9

Vitamin K

MOA: Cofactor in synthesis of active II, VII, IX, X; Indication: Warfarin Toxicity, Gastrinectomy, Hypoprothrombinemia

10

Apixaban, Rivaroxiban, Edoxiban

MOA: Direct inhibition of Xa; Indication: DVT, Afib, Hypercoaguable state

11

Dabigatran

MOA: Direct inhibition of IIa; Indication: DVT, Afib, Hypercoaguable state

12

Aspirin

MOA: COX inhibitor, lowering thromboxine and inhibiting platelet aggregation; Indication: ACS, stroke, arterial thrombosis

13

Clopidogrel, Ticagrelor, Prasurgrel

MOA: ADP receptor inhibitor (prodrugs); Indication: ACS, stroke, arterial thrombosis

14

Kangrelor

MOA: ADP receptor inhibitor (no activation required); Indication: ACS, stroke, arterial thrombosis

15

Dipyridamole

MOA: Phosphodiesterase inhibitor (prevents platelet activation); Indication: Arterial Thrombosis, stroke

16

Cilostazol

MOA: Phosphodiesterase inhibitor (vasodilation); Indication: Intermittent Claudication

17

Abciximab, Eptifibatide, Tirofiban

MOA: GPIIb/GPIIIa inhibitors; Indication: ACS, PCI, MI

18

Fish Oil

MOA: Competitive inhibitor of prostaglandin pathway, preventing platelet activation; Indication: Thrombosis Prophylaxis

19

Zileuton, Montelkast, Zarirlkast

MOA: Leukotriene Pathway inhibitors; Indication: Asthma

20

Streptokinase/Urokinase

MOA: Activates Plasminogen to Plasmin, Fibronlysis; Indication: Thombosis, MI, Stroke, PE

21

tPA

MOA: Activates Plasminogen to Plasmin, Fibronlysis; Indication: Thombosis, MI, Stroke, PE

22

Epsilon Amino Caproic Acid and Tranexemic Acid

MOA: Inactivation of tPA; Indication: tPA overdose, Excessive bleeding

23

Statins

MOA: HMG-CoA reducatse inhibitor -> decreases Cholesterol Synthesis, activating SREBP transcription factor, increasing LDLR synthesis, increasing cholesterol clearance in bile; Indication: Hyperlipidemia, High LDL

24

Cholestryramine, Colestpol, Colesevelam

MOA: Binds Bile Acids in small intestine and causes excretion. This activates Cholesterol 7a-Hydroxylase, which uses cholesterol to synthesize more bile acids. Also increases SREBP TF and LDLR.; Indication: Hyperlipidemia, High LDL

25

Ezetimibe

MOA: Inhibits Cholesterol absorbtion at intesting (via NPCL1); Indication: Hyperlipidemia, High LDL

26

Niacin

MOA: Many actions, decreases VLDL synthesis and increases VLDL clearance, while also decreasing LPa(homologue of plasminogen, which competes for tPA), resulting in decreased thrombosis; Indication: High Triglycerides, High LDL, Low HDL

27

Gemfibrozil and Fenofibrate

MOA: Ligand for PPAR Transcription factor, decreasing ApoC3 synthesis (less VLDL production) and increasing LPL synthese, increasing TG breakfown in VLDL to increase VLDL clearance; Indication: High Triglycerides, Low HDL

28

Alirocumab and Evolocumab

MOA: Inhibit PCSK9, resulting in increased recycling of LDL receptors to hepatocyte membranes; Indication: High LDL uncontolled by max statins, Heterozygous FH

29

Lomitapide

MOA: Inhibition of MTP to decrease lipoprotein production; Indication: Homozygous FH

30

Mipomersen

MOA: Antisense mRNA decreasing ApoB100 and ApoB48 production, decreasing Lupoprotein production; Indication: Homozygous FH